الولايات المتحدة · منصات وبيانات · Finviz

Fractyl Health Meets Six-Month Primary Endpoint in Revita Obesity Trial, Supporting FDA Submission Plans

نشره Finviz · الولايات المتحدة منذ 3 ي

Fractyl Health reports statistically significant reductions in weight regain following GLP-1 discontinuation, advancing its Revita treatment toward a potential FDA submission in…

اقرأ المقال كاملًا على Finviz سجّل الدخول للحفظ

يعرض MarketNews العنوان والملخص كما نشرتهما الوسيلة الإعلامية. المقال الكامل متوفر على موقع الناشر. (finviz.com)

يستحق القراءة أيضًا

MarketBeat

30,000 Shares of Truist Financial Corporation $TFC Bought by Fortitude Financial LLC

Seeking Alpha

Rocky Mountain Chocolate Factory outlines strategic alternatives after $6.6M Durango sale-leaseback and $2M loan

The Motley Fool

Pre-IPO Anduril Stock Climbs 50% in 5 Months

MarketWatch

Blood clots are ‘incredibly common,’ even for pro athletes like Jalen Hurts. Here’s what to know.

Investing.com

Earnings call transcript: Zions Bancorporation tops Q3 2026 EPS forecast

CNBC